Nano Dimension Ltd. appointed Nadav Kidron as a Class II independent director effective August 16, 2026. Mr. Kidron currently serves as President and CEO of Oramed Pharmaceuticals Inc. and will also serve on the Audit and Compensation Committees. Additionally, the company disclosed that the 30-day exclusivity period under its non-binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026, and no definitive agreement has been reached. Nano Dimension Ltd. operates in the advanced manufacturing industry, specializing in industrial 3D printing technologies.
